182 related articles for article (PubMed ID: 36043457)
1. CCR7 alterations associated with inferior outcome of adult T-cell leukemia/lymphoma under mogamulizumab treatment.
Sakamoto Y; Ishida T; Masaki A; Murase T; Ohtsuka E; Takeshita M; Muto R; Iwasaki H; Ito A; Kusumoto S; Nakano N; Tokunaga M; Yonekura K; Tashiro Y; Iida S; Utsunomiya A; Ueda R; Inagaki H
Hematol Oncol; 2022 Dec; 40(5):876-884. PubMed ID: 36043457
[TBL] [Abstract][Full Text] [Related]
2. Genomic determinants impacting the clinical outcome of mogamulizumab treatment for adult T-cell leukemia/lymphoma.
Tanaka N; Mori S; Kiyotani K; Ota Y; Gotoh O; Kusumoto S; Nakano N; Suehiro Y; Ito A; Choi I; Ohtsuka E; Hidaka M; Nosaka K; Yoshimitsu M; Imaizumi Y; Iida S; Utsunomiya A; Noda T; Nishikawa H; Ueda R; Ishida T
Haematologica; 2022 Oct; 107(10):2418-2431. PubMed ID: 35417939
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemistry for CCR4 C-terminus predicts CCR4 mutations and mogamulizumab efficacy in adult T-cell leukemia/lymphoma.
Fujii K; Sakamoto Y; Masaki A; Murase T; Tashiro Y; Yonekura K; Utsunomiya A; Ito A; Kusumoto S; Iida S; Ueda R; Ishida T; Inagaki H
J Pathol Clin Res; 2021 Jan; 7(1):52-60. PubMed ID: 33022137
[TBL] [Abstract][Full Text] [Related]
4. A Multicenter Retrospective Study of Mogamulizumab Efficacy in Adult T-Cell Leukemia/Lymphoma.
Iyama S; Sato T; Ohnishi H; Kanisawa Y; Ohta S; Kondo T; Mori A; Tsutsumi Y; Kuroda H; Kakinoki Y; Yamamoto S; Takahashi T; Shindo M; Torimoto Y; Sato K; Iwasaki H; Haseyama Y; Kohda K; Nagamachi Y; Hirayama Y; Sakai H; Hirata Y; Fukuhara T; Ikeda H; Kobune M; Kato J; Kurosawa M
Clin Lymphoma Myeloma Leuk; 2017 Jan; 17(1):23-30.e2. PubMed ID: 27727135
[TBL] [Abstract][Full Text] [Related]
5. The Impact of a Humanized CCR4 Antibody (Mogamulizumab) on Patients with Aggressive-Type Adult T-Cell Leukemia-Lymphoma Treated with Allogeneic Hematopoietic Stem Cell Transplantation.
Kawano N; Kuriyama T; Yoshida S; Kawano S; Yamano Y; Marutsuka K; Minato S; Yamashita K; Ochiai H; Shimoda K; Ishikawa F; Kikuchi I
J Clin Exp Hematop; 2017; 56(3):135-144. PubMed ID: 28331127
[TBL] [Abstract][Full Text] [Related]
6. Clinical Features, Pathological Features, and Treatment Outcomes of 22 Patients with Aggressive Adult T-cell Leukemia-lymphoma Treated with a Humanized CCR4 Antibody (Mogamulizumab) at a Single Institution during a 6-year Period (2012-2018).
Kawano N; Yoshida N; Kawano S; Arakawa F; Miyoshi H; Yamada K; Nakashima K; Yoshida S; Kuriyama T; Tochigi T; Nakaike T; Shimokawa T; Yamashita K; Marutsuka K; Mashiba K; Kikuchi I; Ohshima K
Intern Med; 2019 Aug; 58(15):2159-2166. PubMed ID: 30996180
[TBL] [Abstract][Full Text] [Related]
7. Clinical Impact of a Humanized CCR4 Antibody (Mogamulizumab) in 14 Patients with Aggressive Adult T-cell Leukemia-lymphoma Treated at a Single Institution During a Three-year Period (2012-2014).
Kawano N; Kuriyama T; Sonoda KH; Yoshida S; Yamashita K; Ochiai H; Shimoda K; Ishikawa F; Ueda A; Kikuchi I
Intern Med; 2016; 55(11):1439-45. PubMed ID: 27250049
[TBL] [Abstract][Full Text] [Related]
8. [Adult T cell leukemia-lymphoma with allo-HSCT after treatment for pulmonary involvement with Mogamulizumab].
Kawashima I; Sueki Y; Yamamoto T; Nozaki Y; Nakajima K; Mitsumori T; Kirito K
Rinsho Ketsueki; 2015 Feb; 56(2):210-5. PubMed ID: 25765802
[TBL] [Abstract][Full Text] [Related]
9. Mogamulizumab for the treatment of T-cell lymphoma.
Makita S; Tobinai K
Expert Opin Biol Ther; 2017 Sep; 17(9):1145-1153. PubMed ID: 28649848
[TBL] [Abstract][Full Text] [Related]
10. Mogamulizumab for relapsed adult T-cell leukemia-lymphoma: Updated follow-up analysis of phase I and II studies.
Ishida T; Utsunomiya A; Jo T; Yamamoto K; Kato K; Yoshida S; Takemoto S; Suzushima H; Kobayashi Y; Imaizumi Y; Yoshimura K; Kawamura K; Takahashi T; Tobinai K; Ueda R
Cancer Sci; 2017 Oct; 108(10):2022-2029. PubMed ID: 28776876
[TBL] [Abstract][Full Text] [Related]
11. Effect of anti-CCR4 monoclonal antibody (mogamulizumab) on adult T-cell leukemia-lymphoma: cutaneous adverse reactions may predict the prognosis.
Yonekura K; Kanzaki T; Gunshin K; Kawakami N; Takatsuka Y; Nakano N; Tokunaga M; Kubota A; Takeuchi S; Kanekura T; Utsunomiya A
J Dermatol; 2014 Mar; 41(3):239-44. PubMed ID: 24628073
[TBL] [Abstract][Full Text] [Related]
12. Clinical significance of TP53 mutations in adult T-cell leukemia/lymphoma.
Sakamoto Y; Ishida T; Masaki A; Murase T; Takeshita M; Muto R; Iwasaki H; Ito A; Kusumoto S; Nakano N; Tokunaga M; Yonekura K; Tashiro Y; Iida S; Utsunomiya A; Ueda R; Inagaki H
Br J Haematol; 2021 Nov; 195(4):571-584. PubMed ID: 34405395
[TBL] [Abstract][Full Text] [Related]
13. Mogamulizumab for the Treatment of Adult T-cell Leukemia/Lymphoma.
Ureshino H; Kamachi K; Kimura S
Clin Lymphoma Myeloma Leuk; 2019 Jun; 19(6):326-331. PubMed ID: 30981611
[TBL] [Abstract][Full Text] [Related]
14. Clinical impact of the CONUT score and mogamulizumab in adult T cell leukemia/lymphoma.
Ureshino H; Kusaba K; Kidoguchi K; Sano H; Nishioka A; Itamura H; Yoshimura M; Yokoo M; Shindo T; Kubota Y; Ando T; Kojima K; Sueoka E; Kimura S
Ann Hematol; 2019 Feb; 98(2):465-471. PubMed ID: 30264165
[TBL] [Abstract][Full Text] [Related]
15. Mogamulizumab for the treatment of relapsed or refractory adult T-cell leukemia-lymphoma.
Winsett FT; Lewis DJ; Duvic M
Expert Rev Hematol; 2017 Sep; 10(9):757-760. PubMed ID: 28756726
[TBL] [Abstract][Full Text] [Related]
16. Clinical efficacy of mogamulizumab for relapsed/refractory aggressive adult T-cell leukemia/lymphoma: A retrospective analysis.
Satake A; Konishi A; Azuma Y; Tsubokura Y; Yoshimura H; Hotta M; Nakanishi T; Fujita S; Nakaya A; Ito T; Ishii K; Nomura S
Eur J Haematol; 2020 Dec; 105(6):704-711. PubMed ID: 32564395
[TBL] [Abstract][Full Text] [Related]
17. Development of a novel Indium-111 radiolabeled mogamulizumab targeting CCR4 for imaging adult T-cell leukemia/lymphoma in vivo.
Shimizu Y; Koyasu S; Suzukida M; Izumi K; Kidera E; Shindo T; Saga T; Ono M; Takaori-Kondo A; Nakamoto Y
Ann Nucl Med; 2022 Mar; 36(3):319-326. PubMed ID: 35034259
[TBL] [Abstract][Full Text] [Related]
18. Mogamulizumab for the treatment of adult T-cell leukemia/lymphoma.
de Lartigue J
Drugs Today (Barc); 2012 Oct; 48(10):655-60. PubMed ID: 23110261
[TBL] [Abstract][Full Text] [Related]
19. CCR4 is rarely expressed in CCR4-mutated T/NK-cell lymphomas other than adult T-cell leukemia/lymphoma.
Sakamoto Y; Fujii K; Murase S; Nakano S; Masaki A; Murase T; Kusumoto S; Iida S; Utsunomiya A; Ueda R; Ishida T; Inagaki H
Int J Hematol; 2019 Oct; 110(4):389-392. PubMed ID: 31468320
[TBL] [Abstract][Full Text] [Related]
20. [Adult T-cell leukemia-lymphoma complicated by Takotsubo cardiomyopathy and HTLV-1-associated myelopathy after treatment with the anti-CCR4 antibody mogamulizumab].
Yamanaka S; Nakayama K; Tamai H; Sakamaki M; Inokuchi K
Rinsho Ketsueki; 2017; 58(4):309-314. PubMed ID: 28484158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]